Laverock Therapeutics expands seed funding and announces key milestone progress
- Laverock Therapeutics closes additional seed funding round, bringing total raised to more than £20m
- Functional data has been generated, demonstrating enhanced tumour control for both primary T-cell and Macrophage programmes, representing key milestones
- Company launches updated website to reflect platform progress and showcase partnering opportunities
London, UK, 30th June 2025/ Laverock Therapeutics, a gene control company powering the development of disease-responsive advanced therapies, announces the expansion of its seed funding round, taking the total raised to more than £20m. The investment was led by Calculus Capital, with participation from existing investors Eli Lilly and Company, Mercia Ventures, Eos Advisory and Maven Capital Partners. The company also welcomed new investor, Norcliffe Capital.
This additional investment marks a transformational period for Laverock. The company has achieved platform development and validation and is transitioning to lead product selection, reporting positive functional data for both its primary T-cell and Macrophage programmes, demonstrating enhanced tumour control in haematological and solid tumour cancer models. Laverock’s unique platform technologies provide the potential to transform the efficacy, precision and safety of advanced therapies, through implementation of its programmable, tunable and multiplex gene silencing approach.
Elizabeth Klein, Investment Director at Calculus, said: “We are delighted to continue our support for Laverock’s progress in pioneering a new era of programmable advanced therapies. This new data and expanded funding demonstrate the potential of Laverock’s technologies. We look forward to continuing our work with David and the team as they drive forward product development opportunities, as well as delivering value for our investors.”
David Venables, CEO of Laverock, added: “The Laverock team has been busy over recent months, continuing to validate our technology platforms but also generating functional data for our therapeutic programmes. This new funding will enable us to continue this development, as well as forming partnerships and collaborations to integrate our technologies into partners’ therapeutic pipelines. I’d like to thank all our existing and new investors for their continued support.”
To reflect Laverock’s recent progress, the company has updated its corporate identity, including the launch of a new website, to demonstrate the expansion of its platform technologies and facilitate an enhanced focus on partnering and outlicensing activities.
ENDS
For further information, please contact:
Sciad Communications, media relations
Juliette Craggs / Maria Taylor
T: +44 (0)20 3405 7892
Laverock Therapeutics
Notes to editors
About Laverock Therapeutics
Laverock Therapeutics is powering the development of disease-responsive advanced therapies through our unique, programmable gene control technology. Our innovative platform harnesses the cell’s natural regulatory mechanisms to deliver programmable and tunable gene control through recoded miRNAs. This enables the development of highly effective medicines with enhanced precision and improved safety profiles.
Utilising our platform technologies, we are working to develop the next-generation of advanced therapies, both through our own pipeline – targeting oncology and genetic medicine – and through partnerships.
Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock has raised more than £20m seed funding to date from high-calibre investors including Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos Advisory, UK Innovation & Science Seed Fund, Tekfen Ventures and Norcliffe Capital.
For more information, please visit www.laverocktx.com and follow us on LinkedIn.